Enochian BioSciences to Present to Investors at 22nd Annual H.C. Wainwright Global Investment Conference
10 sept. 2020 00h50 HE
|
Enochian Biosciences, Inc.
LOS ANGELES, Sept. 10, 2020 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) − Enochian BioSciences, a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today...
Distinguished Scientific Leaders to Join Enochian BioSciences Hepatitis B Scientific Advisory Board
27 juil. 2020 08h00 HE
|
Enochian Biosciences, Inc.
Drs. Carol Brosgart, Peter Revill and Fabien Zoulim will advise on development of a cure for Hepatitis B LOS ANGELES, July 27, 2020 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) − Enochian BioSciences, a...
Enochian BioSciences Announces Its Successful Completion of FDA INTERACT Meeting for a Potential Cure for HIV
08 juin 2020 07h30 HE
|
Enochian Biosciences, Inc.
Company encouraged by strong alignment with views of FDA’s CBER regarding ENOB-HV-01LOS ANGELES, June 08, 2020 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) - Enochian BioSciences, Inc., a company focused on...
Enochian Biosciences Announces Three Scientific Presentations on Potential HIV and HBV Cures
13 mai 2020 08h00 HE
|
Enochian Biosciences, Inc.
• First presentation of a novel approach to potentially cure HIV - An in vivo study demonstrated a 164 percent increase in engraftment of genetically modified cells Poster Presentation -...
Enochian Biosciences Announces Scientific Presentations at the American Society of Cell and Gene Therapy (ASCGT) Annual Meeting
09 avr. 2020 10h00 HE
|
Enochian Biosciences, Inc.
Three of three abstracts were accepted for presentation at the Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT);The presentations advance the scientific foundation of Enochian’s...
Enochian Biosciences Announces FDA INTERACT Meeting for a Potential Cure for HIV
24 févr. 2020 07h30 HE
|
Enochian Biosciences, Inc.
FDA has granted Enochian an INTERACT meeting for its innovative approach to autologous stem cell transplantation as a potential cure for HIV. INTERACT is the first available FDA interaction and is a...
Enochian Biosciences Acquires an Exclusive License for a Novel Hepatitis B Virus Potential Treatment or Cure
03 févr. 2020 07h30 HE
|
Enochian Biosciences, Inc.
LOS ANGELES, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Enochian Biosciences, a company focused on gene-modified cellular therapy in infectious diseases and cancer, announces that it has finalized the...
Enochian Biosciences, a company focused on gene-modified cellular therapy in infectious disease and cancer, announces the appointment of two board members:
06 janv. 2020 07h30 HE
|
Enochian Biosciences, Inc.
- Gregg Alton, the former interim CEO of Gilead Sciences, a company he served in many key roles during his more than 20 year tenure, and; - Carol Brosgart, MD, Clinical Professor of Medicine at the...
Enochian Biosciences Announces Scientific Presentation of a Novel Approach to Potentially Cure Hepatitis B Virus
10 déc. 2019 07h00 HE
|
Enochian Biosciences, Inc.
A new gene therapy kills up to 98 percent of HBV infected cells but not uninfected cells. Results from a commonly used mouse model to study HBV confirmed the HBV-infected cell-specific killing effect...
Enochian Biosciences Expands its Infectious Disease Pipeline by Entering into an Agreement in Principle to Acquire an Exclusive License for a Novel Hepatitis B Virus Treatment
25 nov. 2019 07h00 HE
|
Enochian Biosciences, Inc.
Agreement provides Enochian with exclusive rights to develop and commercialize a HBV treatment with a novel mechanism of actionAbstract accepted highlighting the in vivo and in vitro data from...